Lapatinib, an oral tyrosine kinase inhibitor selective for inhibition of HER1, HER2, and HER1/HER2-dependent downstream signaling pathways (17), has been widely applied in successfully treating HER2-positive breast, colorectal, and non-small-cell lung cancers (18, 19). This evidence concerns the gene EGFR and non-small cell lung carcinoma.